Increased expression of the receptor for advanced glycation end-products in human peripheral neuropathies

Brain and Behavior

Volumn 3, Issue 6, 2013, Pages 701-709

  Juranek, Judyta K ^a,b   Kothary, Pratik ^a,b   Mehra, Alka ^b   Hays, Arthur ^a   Brannagan, Thomas H ^a   Schmidt, Ann Marie ^a,b  

^a NewYork Presbyterian Hospital   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Diabetes; Human; Peripheral neuropathy; RAGE; RAGE ligands

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; MAMMALIAN DIAPHANOUS 1; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC PATIENT; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IDIOPATHIC DISEASE; MALE; NERVE BIOPSY; NERVOUS SYSTEM ELECTROPHYSIOLOGY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SURAL NERVE;

EID: 84893448611     PISSN: None     EISSN: 21623279     Source Type: Journal    
DOI: 10.1002/brb3.176     Document Type: Article

References (40)

1. Anzilotti, S., C. Giampa, D. Laurenti, L. Perrone, G. Bernardi, M. A. Melone, et al. 2012. Immunohistochemical localization of receptor for advanced glycation end (RAGE) products in the R6/2 mouse model of Huntington's disease. Brain Res. Bull. 87:350-358.
2. Baarlink, C., D. Brandt, and R. Grosse. 2010. SnapShot: formins. Cell 142:172, 172 e171.
3. Barohn, R. J. 1998. Approach to peripheral neuropathy and neuronopathy. Semin. Neurol. 18:7-18.
4. Bierhaus, A., K. M. Haslbeck, P. M. Humpert, B. Liliensiek, T. Dehmer, M. Morcos, et al. 2004. Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J. Clin. Investig. 114:1741-1751.
5. Bierhaus, A., P. M. Humpert, M. Morcos, T. Wendt, T. Chavakis, B. Arnold, et al. 2005. Understanding RAGE, the receptor for advanced glycation end products. J. Mol. Med. (Berl.) 83:876-886.
6. Brenn, A., M. Grube, M. Peters, A. Fischer, G. Jedlitschky, H. K. Kroemer, et al. 2011. Beta-amyloid downregulates MDR1-P-glycoprotein (Abcb1) expression at the blood-brain barrier in mice. Int. J. Alzheimers Dis. 2011:690121.
7. Donofrio, P. D. 2012. Textbook of peripheral neuropathy. Demos Medical Publishing, New York, NY.
8. Dyck, P. J., K. F. Oviatt, and E. H. Lambert. 1981. Intensive evaluation of referred unclassified neuropathies yields improved diagnosis. Ann. Neurol. 10:222-226.
9. Faraco, G., S. Fossati, M. E. Bianchi, M. Patrone, M. Pedrazzi, B. Sparatore, et al. 2007. High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo. J. Neurochem. 103:590-603.
10. Feldman, P., M. R. Due, M. S. Ripsch, R. Khanna, and F. A. White. 2012. The persistent release of HMGB1 contributes to tactile hyperalgesia in a rodent model of neuropathic pain. J. Neuroinflammation 9:180.
11. Goh, W. I., K. B. Lim, T. Sudhaharan, K. P. Sem, W. Bu, A. M. Chou, et al. 2012. mDia1 and WAVE2 proteins interact directly with IRSp53 in filopodia and are involved in filopodium formation. J. Biol. Chem. 287:4702-4714.
12. Haslbeck, K. M., E. D. Schleicher, U. Friess, A. Kirchner, B. Neundorfer, and D. Heuss. 2002. N(epsilon)-Carboxymethyllysine in diabetic and non-diabetic polyneuropathies. Acta Neuropathol. 104:45-52.
13. Haslbeck, K. M., A. Bierhaus, S. Erwin, A. Kirchner, P. Nawroth, U. Schlotzer, et al. 2004. Receptor for advanced glycation endproduct (RAGE)-mediated nuclear factor-kappaB activation in vasculitic neuropathy. Muscle Nerve 29:853-860.
14. Haslbeck, K. M., E. Schleicher, A. Bierhaus, P. Nawroth, M. Haslbeck, B. Neundorfer, et al. 2005. The AGE/RAGE/NF-(kappa)B pathway may contribute to the pathogenesis of polyneuropathy in impaired glucose tolerance (IGT). Exp. Clin. Endocrinol. Diabetes 113:288-291.
15. Haslbeck, K. M., B. Neundorfer, U. Schlotzer-Schrehardtt, A. Bierhaus, E. Schleicher, E. Pauli, et al. 2007. Activation of the RAGE pathway: a general mechanism in the pathogenesis of polyneuropathies? Neurol. Res. 29:103-110.
16. Hori, O., J. Brett, T. Slattery, R. Cao, J. Zhang, J. X. Chen, et al. 1995. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem. 270:25752-25761.
17. Hudson, B. I., A. Z. Kalea, M. Del Mar Arriero, E. Harja, E. Boulanger, V. D'Agati, et al. 2008. Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J. Biol. Chem. 283:34457-34468.
18. Juranek, J. K., A. Aleshin, E. M. Rattigan, L. Johnson, W. Qu, F. Song, et al. 2010. Morphological changes and immunohistochemical expression of RAGE and its ligands in the sciatic nerve of hyperglycemic pig (Sus scrofa). Biochem. Insights 2010:47-59.
19. Juranek, J. K., M. S. Geddis, F. Song, J. Zhang, J. Garcia, R. Rosario, et al. 2013. RAGE deficiency improves postinjury sciatic nerve regeneration in type 1 diabetic mice. Diabetes 62:931-943.
20. Kawai, T., I. Takei, M. Tokui, O. Funae, K. Miyamoto, M. Tabata, et al. 2010. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(varepsilon)-carboxymethyl lysine. J. Diabetes Complications 24:424-432.
21. Lotze, M. T., and K. J. Tracey. 2005. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 5:331-342.
22. Muhammad, S., W. Barakat, S. Stoyanov, S. Murikinati, H. Yang, K. J. Tracey, et al. 2008. The HMGB1 receptor RAGE mediates ischemic brain damage. J. Neurosci. 28:12023-12031.
23. Rai, V., A. Y. Maldonado, D. S. Burz, S. Reverdatto, S. F. Yan, A. M. Schmidt, et al. 2012. Signal transduction in receptor for advanced glycation end products (RAGE): solution structure of C-terminal rage (ctRAGE) and its binding to mDia1. J. Biol. Chem. 287:5133-5144.
24. Ramasamy, R., S. F. Yan, and A. M. Schmidt. 2007. Arguing for the motion: yes, RAGE is a receptor for advanced glycation endproducts. Mol. Nutr. Food Res. 51:1111-1115.
25. Rong, L. L., C. Gooch, M. Szabolcs, K. C. Herold, E. Lalla, A. P. Hays, et al. 2005. RAGE: a journey from the complications of diabetes to disorders of the nervous system - striking a fine balance between injury and repair. Restor. Neurol. Neurosci. 23:355-365.
26. Rose, R., M. Weyand, M. Lammers, T. Ishizaki, M. R. Ahmadian, and A. Wittinghofer. 2005. Structural and mechanistic insights into the interaction between Rho and mammalian Dia. Nature 435:513-518.
27. Schmidt, A. M., O. Hori, R. Cao, S. D. Yan, J. Brett, J. L. Wautier, et al. 1996. RAGE: a novel cellular receptor for advanced glycation end products. Diabetes 45(Suppl 3):S77-S80.
28. Schmidt, A. M., S. D. Yan, S. F. Yan, and D. M. Stern. 2000. The biology of the receptor for advanced glycation end products and its ligands. Biochim. Biophys. Acta 1498:99-111.
29. Shibasaki, M., M. Sasaki, M. Miura, K. Mizukoshi, H. Ueno, S. Hashimoto, et al. 2010. Induction of high mobility group box-1 in dorsal root ganglion contributes to pain hypersensitivity after peripheral nerve injury. Pain 149:514-521.
30. Shinohara, R., D. Thumkeo, H. Kamijo, N. Kaneko, K. Sawamoto, K. Watanabe, et al. 2012. A role for mDia, a Rho-regulated actin nucleator, in tangential migration of interneuron precursors. Nat. Neurosci. 15:S371-S372.
31. Sousa, M. M., and M. J. Saraiva. 2003. Neurodegeneration in familial amyloid polyneuropathy: from pathology to molecular signaling. Prog. Neurobiol. 71:385-400.
32. Sugimoto, K., Y. Nishizawa, S. Horiuchi, and S. Yagihashi. 1997. Localization in human diabetic peripheral nerve of N(epsilon)-carboxymethyllysine-protein adducts, an advanced glycation endproduct. Diabetologia 40:1380-1387.
33. Sugimoto, K., M. Yasujima, and S. Yagihashi. 2008. Role of advanced glycation end products in diabetic neuropathy. Curr. Pharm. Des. 14:953-961.
34. Takeuchi, M., R. Bucala, T. Suzuki, T. Ohkubo, M. Yamazaki, T. Koike, et al. 2000. Neurotoxicity of advanced glycation end-products for cultured cortical neurons. J. Neuropathol. Exp. Neurol. 59:1094-1105.
35. Teismann, P., K. Sathe, A. Bierhaus, L. Leng, H. L. Martin, R. Bucala, et al. 2012. Receptor for advanced glycation endproducts (RAGE) deficiency protects against MPTP toxicity. Neurobiol. Aging 33:2478-2490.
36. Tian, L., H. Rauvala, and C. G. Gahmberg. 2009. Neuronal regulation of immune responses in the central nervous system. Trends Immunol. 30:91-99.
37. Toth, C., L. L. Rong, C. Yang, J. Martinez, F. Song, N. Ramji, et al. 2008. Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy. Diabetes 57:1002-1017.
38. Vicente Miranda, H., and T. F. Outeiro. 2010. The sour side of neurodegenerative disorders: the effects of protein glycation. J. Pathol. 221:13-25.
39. Witzke, K. A., A. I. Vinik, L. M. Grant, W. P. Grant, H. K. Parson, G. L. Pittenger, et al. 2011. Loss of RAGE defense: a cause of Charcot neuroarthropathy? Diabetes Care 34:1617-1621.
40. Younger, D. S., G. Rosoklija, A. P. Hays, W. Trojaborg, and N. Latov. 1996. Diabetic peripheral neuropathy: a clinicopathologic and immunohistochemical analysis of sural nerve biopsies. Muscle Nerve 19:722-727.